HyperSKIN: HYPERspectral monitoring for accurate light-based SKIN cancer treatment
Topic: ERC-2024-POC
Type of Action: HORIZON-ERC-POC
Grant Agreement: 101212894
The increasing incidence of non-melanoma skin cancer (NMSC, 330,000 new cases in Europe,2022), due to increase of elderly population, unprotected sun exposure and still poor prevention, is a huge public health concern worldwide. Recurrences and consequent need for repeated surgery are mainly associated with incomplete excision and positive tumor margins persistence. Also, typical surgical risks of poor scarring, infection, pain, and time-consuming histopathological analysis demand innovative approaches, like light-based therapies, considered safe and effective options for many NMSC cases. However, none of traditional and new approaches perform treatment intraoperative control, thus leading to cancer progression and recurrence.
To overcome the lack of intraoperative monitored NMSC treatments, HyperSKIN develops a contactless device based on hyperspectral imaging that revolutionizes the decision-making regarding excisional margins before and during the procedure, with instantaneous feedback on the skin regions to be preserved and the tumoral parts to be removed. HyperSKIN will be also used to guide a light-based localized treatment of the cancer.
Within this PoC, the team will perform the technical-commercial feasibility study to move the HyperSKIN system to the market. I will prototype the HyperSKIN system and establish contacts with stakeholders for HyperSKIN validation and integration in clinical practice. The PoC will set a market and health technology assessment, the IP protection strategy, and identify the best business model and exploitation strategy for valorising the know-how.
To know more:
